Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

bladder tumor childhood exposure environmental smoking nonsmoking adult

*Cystectomy *Health Status Humans Patient Education as Topic/*methods Preoperative Care/*methods Relaxation Therapy/*methods Urinary Bladder Neoplasms/*surgery Bladder cancer Cystectomy Supportive intervention Systematic review PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Circulating Tumor DNA/*analysis/blood/urine Humans Reproducibility of Results Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/pathology CfDNA biomarkers diagnosis meta-analysis

Aminolevulinic Acid/*chemistry Cystoscopy/methods Humans Image Interpretation Computer-Assisted/*methods Narrow Band Imaging/methods Photosensitizing Agents/*chemistry Urinary Bladder Neoplasms/metabolism/pathology/*surgery Narrow band imaging bladder cancer diagnostic performance photodynamic diagnosis white light-guided cystoscopy

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Periodontal diseases cohort studies meta-analysis periodontitis urinary bladder neoplasms

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

bladder cancer meta-analysis system review tumor associated macrophages

Aged Biomarkers Tumor/*blood Cystectomy/*adverse effects Female Humans Leukocyte Count Lymphocytes/*pathology Male Middle Aged Monocytes/*pathology Neoplasm Recurrence Local/blood/*epidemiology Postoperative Complications/blood/*epidemiology Survival Analysis Urinary Bladder Neoplasms/*blood/pathology/surgery

Biomarkers Tumor/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*urine Biomarker Bladder cancer Diagnosis Systematic review Urine

Adult Case-Control Studies Child Environmental Exposure/*adverse effects/analysis Humans Odds Ratio Risk Factors Tobacco Smoke Pollution/*adverse effects/analysis Urinary Bladder Neoplasms/*epidemiology Workplace bladder cancer exposure to environmental tobacco smoke lifetime exposure meta-analysis

Bladder cancer Coffee Cohort studies Meta-analysis

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Cisplatin/administration & dosage Deoxycytidine/administration & dosage/analogs & derivatives Doxorubicin/administration & dosage Humans Methotrexate/administration & dosage Muscle Neoplasms/*drug therapy/pathology Neoplasm Invasiveness Prognosis Survival Rate Urinary Bladder Neoplasms/*drug therapy/pathology Vinblastine/administration & dosage Gemcitabine Bladder cancer and cisplatin chemotherapy doxorubicin/adriamycin gemcitabine and cisplatin methotrexate vinblastine

Antigenic Variation Antigens Neoplasm/*genetics Asian People GPI-Linked Proteins/genetics *Genetic Predisposition to Disease Humans Male Neoplasm Proteins/*genetics Polymorphism Single Nucleotide Urinary Bladder Neoplasms/*genetics White People

Biomarkers Tumor/analysis Carcinoma Papillary/diagnosis/pathology Carcinoma Transitional Cell/diagnosis/pathology Humans Keratin-20/analysis/biosynthesis Prognosis Urinary Bladder Neoplasms/diagnosis/pathology Urologic Neoplasms/diagnosis/*pathology Urothelium/*pathology Cytokeratin 20 Molecular subtyping Thelial carcinoma Uro Urothelial lesions Variant histology

Female Humans Male Prospective Studies Sex Factors Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder cancer Cystitis Urinary bladder neoplasms Urinary tract infections Urothelial carcinoma

Carcinoma Transitional Cell/epidemiology/*surgery *Cystectomy Humans Kidney Neoplasms/*epidemiology Neoplasms Second Primary/*epidemiology Ureteral Neoplasms/*epidemiology Urethral Neoplasms/*epidemiology Urinary Bladder Neoplasms/*surgery Bladder cancer Radical cystectomy Recurrence Remnant Upper urinary tract Urethra Urothelium including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.